XAMS
CRBN
Market cap1.59bUSD
Oct 20, Last price
24.28EUR
1D
3.32%
1Q
26.33%
Jan 2017
-4.52%
Name
Corbion NV
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Corbion NV engages in the development, production, sale, and distribution of ingredients for food and biochemicals. It operates through the following segments: Food and Biochemicals. The Food segment provides biobased ingredients for the food industry. The Biochemicals segment produces chemicals derived from organic acids through the fermentation of carbohydrates, and lactic acid based solutions. The company was founded on August 21, 1919 and is headquartered in Amsterdam, the Netherlands.
Related entities
Subsidiaries (4)
Expalkan V. B.V.
Purac Biochem B.V.
PURAC BIOQUIMICA S.A.
TotalEnergies Corbion B.V.
Key people
Chairman Board of Management and Executive Committee, Chief Executive Officer · since 2019
Peter Kazius
Chief Financial Officer, Member Board of Management and Executive Committee · since 2024
Jacqueline Van Lemmen
Chief Operations Officer, Member of the Executive Committee · since 2020
Masha Vis-Mertens
Chief Human Resources Officer, Member of the Executive Committee · since 2024
Jennifer Lindsey
Chief Marketing and Digital Officer, Member of the Executive Committee · since 2022
Rudd Peerbooms
President Health and Nutrition, Member of the Executive Committee · since 2020
Chairman of the Supervisory Board · since 2025
Mathieu Vrijsen
Independent Chairman of the Supervisory Board · since 2015
Abhijit Bhattacharya
Member of the Supervisory Board · since 2025
Elizabeth Doherty
Independent Member of the Supervisory Board · since 2015
Karen Marie Katholm
Member of the Supervisory Board · since 2025
William Lin
Member of the Supervisory Board · since 2022
Steen Riisgaard
Independent Member of the Supervisory Board · since 2014
Member of the Supervisory Board · since 2021
Headquarters & legal address
Piet Heinkade 127
Amsterdam 1019GM
NL
Amsterdam 1019GM
NL
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||